Benzinga's Top #PreMarket Gainers

shares jumped 18.93% to $7.35 in pre-market trading after the company reported topline results of Phase IIa pharmacokinetic study of ND0612H And ND0612L.

shares jumped 11.78% to $9.30 in pre-market trading following positive comments from RBC's Michael Yee.

shares rose 6.80% to $10.36 in pre-market trading. Repros Therapeutics initiated two Phase 2B uterine fibroid studies. The company is expecting dossier to be filed by end of first quarter.

shares surged 6.13% to $9.00 in pre-market trading following the disclosure of a 7.1% stake by Corvex and confirmation of discussions with the company.

shares gained 5.99% to $2.30 in the pre-market trading session as the company announced that it will regain rights to custirsen from Teva Pharmaceutical Industries Ltd.

.